Moderna, Inc., a renowned biotechnology firm pioneering the field of messenger RNA therapeutics as well as vaccines to develop the next generation of medicines, has reportedly announced a new supply deal with the Government of United Kingdom to ship an extra two million mRNA-1273 doses, the company’s COVID-19 vaccine candidate, to the country beginning March 2021. The UK has now secured over seven million doses of Moderna mRNA-1273. This new confirmation arrives as the country continues its ongoing efforts to secure an effective and safe access to COVID-19 vaccines by
With many countries experiencing a second wave of COVID-19, faster patient diagnosis has become vital for curbing the spread of the contagious virus. Some researchers in the U.S. have recently made efforts to address this issue by developing a new AI (artificial intelligence) platform that detects Covid-19 by examining X-ray images of the lungs. Dubbed DeepCOVID-XR, the machine learning (ML) algorithm was reportedly claimed to have outpaced a team of thoracic radiologists in spotting COVID-19 in X-rays, at a rate 10 times faster along with more accuracy. 
The rapid developments of AI-based technologies are likely to revolutionize human social life and the world. Governments worldwide have started taking proactive steps to seize lucrative opportunities in this field. Recently, a similar instance comes to light when Chengdu, the capital city of China's Sichuan province, announced plans to develop a national pilot zone for advancing AI technologies. Chengdu municipal government announced an action plan to promote the development of an AI-based pilot zone in November. It will invest over USD 15.2 billion in more than 170 majo
As most of the world is witnessing a second wave of COVID-19, the next big thing in battling this highly contagious disease could come from an innovative antibody testing designed particularly to achieve a rapid diagnosis. As per the latest news, BASE10 Genetics Inc. and DNA Link Inc. have reportedly partnered to assess the usability of new antibody-based testing, entering the global race to find novel ways to develop rapid coronavirus disease testing method. Sources cite that both companies will jointly work on a research project to asse
China-based ByteDance has reportedly obtained an extension period of seven days from the U.S. administration over an earlier order that directed the company to sell its TikTok app within a period of 90 days. Sources with the knowledge of the matter state that ByteDance has initiated a new proposal for addressing the concerns of the U.S. government, much information on which is not yet available. According to a representative of the U.S. Treasury, the extension has been granted for reviewing a recently secured “revised submission”.
Poco has reportedly made an announcement via its social media channels, whereby the company will soon be securing an independent identity at the global level. The move comes after more than 10 months following the separation of the company’s Indian subsidiary from Xiaomi. For the uninitiated, Poco was launched in 2018 as a sub-brand of Xiaomi. The brand initially acquired popularity among young smartphone clientele via its Poco F1. However, Poco’s roll out of phones in the recent past has appeared to be a rebadging of some existing Redmi models.
Fujitsu, a leading Japanese multinational IT equipment and services company, has reportedly announced the commercial launch of its novel medical solution inside the Japanese market. The new solution would give medical workers a powerful novel tool for supporting COVID-19 countermeasures on the frontlines and further promote the digital transformation of doctors’ work across hospitals and medical establishments. The novel solution links Fujitsu’s entire EMR systems, effectively ranging from larger hospitals to small clinics, with availability in Japan starting 25
Polaryx Therapeutics Inc., a South Korea-based biotech company that develops small molecule therapeutics for lysosomal storage disorders treatment, has reportedly announced that its GM2 gangliosidosis treatment drug PLX-300 has received Rare Pediatric Disease as well as Orphan Drug designations from the U.S. Food and Drug Administration (FDA). For those uninitiated, key enzymes in the lysosome genes, namely, Hexosaminidase A (HEXA) and Hexosaminidase B (HEXB), have defects that can lead to to ultra-rare and fatal pediatric neurodegenerative disorders
Bitcoin Latinum, the new cryptocurrency based on the Bitcoin ecosystem, has reportedly announced its official pre-sale launch. The new cryptocurrency will be trading under the symbol LTNM with a supply of 888,888,888 LTNM Sources cite that Bitcoin Latinum is currently available for pre-sale on bitcoinlatinum.com and is expected to be available on exchanges in 2021. The cryptocurrency is an improved Bitcoin fork that is set to revolutionize cross-border payments and digital transactions. It incorpor